plx pharma inc. is a biotechnology company located in 8285 el rio, suite 130, houston, tx, united states.
Company profile
Ticker
PLXPQ
Exchange
Website
CEO
Ronald Zimmerman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Dipexium Pharmaceuticals, Inc., Dipexium Pharmaceuticals, LLC, PLx Pharma Inc.
SEC CIK
Corporate docs
Subsidiaries
PLx Opco Inc. ...
PLXPQ stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
18 Oct 23
8-K
Bankruptcy or Receivership
20 Sep 23
8-K
Other Events
22 Aug 23
8-K
Other Events
21 Jul 23
8-K
Other Events
12 Jul 23
8-K
Departure of Directors or Certain Officers
7 Jul 23
8-K
Other Events
27 Jun 23
8-K
Entry into a Material Definitive Agreement
26 May 23
25-NSE
Exchange delisting
2 May 23
8-K
Bankruptcy or Receivership
13 Apr 23
Transcripts
PLXPQ
Earnings call transcript
2022 Q3
11 Nov 22
PLXPQ
Earnings call transcript
2022 Q2
12 Aug 22
PLXPQ
Earnings call transcript
2022 Q1
13 May 22
PLXPQ
Earnings call transcript
2021 Q4
11 Mar 22
PLXPQ
Earnings call transcript
2021 Q3
12 Nov 21
PLXPQ
Earnings call transcript
2021 Q2
7 Aug 21
PLXPQ
Earnings call transcript
2021 Q1
14 May 21
PLXPQ
Earnings call transcript
2020 Q4
12 Mar 21
PLXPQ
Earnings call transcript
2020 Q3
16 Nov 20
PLXPQ
Earnings call transcript
2020 Q2
14 Aug 20
Latest ownership filings
SC 13G
Park West Asset Management LLC
6 Apr 23
SC 13G/A
MSD Partners, L.P.
14 Feb 23
4
Natasha Giordano
16 Mar 22
4
Rita M O'Connor
16 Mar 22
4
Michael J Valentino
24 Feb 22
4
Rita M O'Connor
24 Feb 22
4
JOHN HADDEN
24 Feb 22
4
Natasha Giordano
24 Feb 22
4
Robert Casale
24 Feb 22
4
KIRK K CALHOUN
24 Feb 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.83 mm | 25.83 mm | 25.83 mm | 25.83 mm | 25.83 mm | 25.83 mm |
Cash burn (monthly) | 3.30 mm | 3.63 mm | 3.61 mm | 5.37 mm | 3.66 mm | 4.94 mm |
Cash used (since last report) | 61.97 mm | 68.20 mm | 67.87 mm | 100.85 mm | 68.77 mm | 92.88 mm |
Cash remaining | -36.13 mm | -42.36 mm | -42.04 mm | -75.02 mm | -42.93 mm | -67.05 mm |
Runway (months of cash) | -11.0 | -11.7 | -11.6 | -14.0 | -11.7 | -13.6 |
Institutional ownership, Q2 2023
23.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 1 |
Closed positions | 29 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 45.06 mm |
Total shares | 7.15 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
White Rock Capital Management | 2.81 mm | $22.52 mm |
Level One Partners | 2.77 mm | $22.21 mm |
Park West Asset Management | 1.44 mm | $172.00 k |
O'Brien Greene & Co. | 66.00 k | $0.00 |
Steward Partners Investment Advisory | 43.88 k | $123.00 k |
Baader Bank | 17.61 k | $38.00 k |
Simplex Trading | 100.00 | $0.00 |